Sponsored by:

American Diabetes Association

71st Scientific Sessions | June 24-28, 2011 - San Diego, CA

ADA Scientific Session 2011
Note that some of these links take you to a site outside of CardioSource.
CardioSource does not assume responsibility for content of external sites.

Thursday June 30 2011

  • One Extra Insulin Dose as Effective as Three

    SAN DIEGO — Adding one additional dose of insulin to the basal dosage may be as effective in controlling blood glucose levels as adding two or three doses at mealtimes in patients with type 2 diabetes, researchers suggested here.

  • Prophylactic Metformin Cuts Medical Costs

    SAN DIEGO — Starting patients on metformin and lifestyle interventions are both cost-effective means of preventing diabetes in at-risk patients, researchers said here.

  • Public Knows About Diabetes, Takes No Action

    SAN DIEGO — By and large, Americans are well informed about the risks, dangers, and signs of diabetes — but that knowledge does not appear to translate into actions to prevent or control the disease, researchers reported here.

  • Tiny Pump Helps Improve Glycemic Control

    SAN DIEGO — A matchstick-sized implantable subcutaneous pump that delivers a steady flow of the GLP-1 agonist exenatide (Byetta) maintained improvements in glycemic control over a year, researchers said here.

  • Unintended Glucose Patterns Predict Death

    SAN DIEGO — Day-to-day glucose levels that stray too high when tight control is the aim or too low when therapy isn't intense may signal mortality risk, an ACCORD trial subanalysis indicated.

Wednesday June 29 2011

  • Insulin Pump Suspend Feature Halts Hypoglycemia

    SAN DIEGO — Insulin pumps that automatically shut down when blood glucose hits a certain low level decrease the amount of time pediatric patients spend in hypoglycemia, researchers said here.

  • Diabetics Lead Peers to Healthier Status

    SAN DIEGO — Training people with diabetes to teach other patients improves utilization of medications and results in lifestyle changes — and also brings long-term benefits, researchers said here.

  • Linagliptin Works in Diabetic Kidney Disease

    SAN DIEGO — Type 2 diabetes patients with impaired renal function saw significant drops in HbA1c after treatment with linagliptin (Tradjenta) when compared with placebo, researchers said here.

  • Novel Drug Controls Glucose, but May Have Cancer Risk

    SAN DIEGO — The novel SGLT2 inhibitor dapagliflozin produced superior glycemic control over placebo when added to metformin, although there were faint signals of bladder and breast cancer cases in the drug groups, researchers said here.

  • Vascular Status Predicts Hypoglycemia

    SAN DIEGO — Type 2 diabetes patients with microvascular or macrovascular complications, or those taking certain monotherapies, are more likely to experience hypoglycemia and require outpatient hospital visits, researchers said here.

Tuesday June 28 2011

  • Anti-VEGF 'Impressive' in Sharpening Vision

    SAN DIEGO — The good news continues to roll in for ranibizumab (Lucentis) in diabetic macular edema with positive RIDE and RISE trial results.

  • Biologic Slows Type 1 Diabetes

    SAN DIEGO — The arthritis drug abatacept (Orencia) may help delay progression of type 1 diabetes, according to randomized clinical trial results.

  • Drug Misses Type 1 Goal, but May Help Beta Cells

    SAN DIEGO — Although treatment with the monoclonal antibody teplizumab doesn't appear to improve glycemic control or reduce insulin dose among patients with type 1 diabetes, it may still preserve beta-cell function, researchers said here.

  • Good Efficacy, Safety With Linagliptin

    SAN DIEGO — The recently approved DPP-4 inhibitor linagliptin (Tradjenta) provided comparable control in type 2 diabetes to glimepiride (Amaryl) when added to metformin and cut the risk of cardiovascular events in half, researchers said here.

  • Tight Control No Help After Renal Treatment

    SAN DIEGO — Tight glucose control early after kidney transplantation doesn't improve graft success, researchers found.

Monday June 27 2011

  • Type 1 Diabetes Vaccine Fails to Show Benefit

    SAN DIEGO — An antigen-based immunotherapy has failed to halt the progression of type 1 diabetes after one year, researchers reported here.

  • Early Liraglutide Tx Improves Diabetes Control

    SAN DIEGO — Early treatment with the glucagon-like peptide-1 agonist liraglutide (Victoza) appears to improve type 2 diabetic patients' overall glycemic control when compared with using the injected drug late in the course of the disease, researchers said here.

  • FDA Artificial Pancreas Initiative InFocus

    SAN DIEGO — In this exclusive InFocus report, Chip Zimliki, PhD, chair of the FDA's critical path initiative for the artificial pancreas, discusses the agency's first guidance on premarket approval of closed-loop systems.

  • Type 2 Diabetics Can Alter Lifestyles

    SAN DIEGO — A short-term lifestyle modification program for overweight diabetic patients seen in clinical practice showed long-term benefits for many of the participants, researchers reported here.

  • Docs Worldwide Slow to Start Insulin

    SAN DIEGO — Treatment of diabetes varies greatly in clinical practice worldwide — but there is one constant, researchers said here: Doctors tend to delay treatment with insulin in every region of the globe.

Sunday June 26 2011

  • FDA Unlikely to Zap Pioglitazone

    SAN DIEGO — Bladder cancer risks aren't likely to send the diabetes drug pioglitazone (Actos) down the same path as rosiglitazone (Avandia), according to this exclusive InFocus report from the American Diabetes Association meeting.

  • Diabetes Drug May Help Others Lose Weight

    SAN DIEGO — The diabetes drug liraglutide (Victoza), touted for its weight-loss effects in that patient population, may also help non-diabetic patients keep pounds off, researchers said here.

  • Antipsychotics Change Metabolism in Kids

    SAN DIEGO — Antipsychotics appear to increase body fat and increase the risk of metabolic abnormalities in children and adolescents, researchers said here.

  • Type 1 Diabetes Control Tied to Heart Failure Risk

    SAN DIEGO — Tight glucose control in type 1 diabetes could rein in risk of heart failure as a complication of the disease, population-based study results suggested.

Saturday June 25 2011

  • Cheap Generics Boost Price Tag for Brand Names

    SAN DIEGO — Dramatic increases in brand-name drug pricing at pharmacies across the country have followed the low-price generic programs popularized by Wal-Mart, researchers discovered.

  • Diet Counseling Aids Glycemic Control

    SAN DIEGO — Intensive dietary counseling in the year following a diagnosis of diabetes improved glycemic control, but adding exercise to the mix didn't add any extra benefits, researchers said here.

  • Intensive Tx No Better than Good Routine Diabetes Care

    SAN DIEGO — Screening and early intensive management of type 2 diabetes may hold little benefit beyond usual care, perhaps because of more aggressive routine practice, researchers suggested.

  • Older Diabetics Better at Keeping Weight Off

    SAN DIEGO — Weight loss among diabetic, overweight patients was most durable in those who lost more than 10% of their body weight in the first year and in those 65 and older, researchers said here.

  • Two Tests Needed to Track Diabetes Progression

    SAN DIEGO — Diagnosing prediabetes with a combination of glycated hemoglobin and impaired fasting glucose may be a more effective predictor of progression to diabetes than either test alone, Japanese researchers found.

Thursday June 23 2011

  • Focus Is on Early Management at Meeting

    SAN DIEGO — The best treatments and techniques to use early in the course of type 2 diabetes will highlight sessions here at this year's American Diabetes Association meeting.